Infinity Pharmaceuticals (DB:I3F) - Prezzo delle azioni, notizie e analisi

I3F Panoramica delle azioni

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. Maggiori dettagli

I3F analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	1/6
Dividendi	0/6

Analisi del rischio

Le azioni sono altamente illiquide

Ha meno di 1 anno di pista di cassa

Gli utili sono diminuiti del 14.5% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( €281K )

+ 2 più rischi

Infinity Pharmaceuticals, Inc. Concorrenti

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Paion

DB:PA8K

€42.8k

co.don

XTRA:CNW

€6.5m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Infinity Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.017
Massimo di 52 settimane	US$0.69
Minimo di 52 settimane	US$0.011
Beta	1.64
1Variazione di 1 mese	0%
Variazione a 3 mesi	3.64%
Variazione di 1 anno	-96.42%
3Variazione a 3 anni	-99.01%
Variazione a 5 anni	-98.15%
Variazione dall'IPO	-99.40%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	I3F	DE Biotechs	DE Mercato
7D	0%	-1.1%	1.1%
1Y	-96.4%	-18.8%	7.2%

Ritorno vs Industria: I3F ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -18.8 % nell'ultimo anno.

Rendimento vs Mercato: I3F ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.2 % nell'ultimo anno.

Volatilità dei prezzi

Is I3F's price volatile compared to industry and market?
I3F volatility
I3F Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di I3F è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di I3F nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	30	Seth Tasker	www.infi.com

Infinity Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Infinity Pharmaceuticals con la sua capitalizzazione di mercato?
I3F statistiche fondamentali
Capitalizzazione di mercato	€256.32k
Guadagni(TTM)	-€37.30m
Ricavi(TTM)	€2.34m

0.1x

Rapporto P/S

0.0x

Rapporto P/E

I3F è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
I3F Conto economico (TTM)
Ricavi	US$2.57m
Costo del fatturato	US$28.53m
Profitto lordo	-US$25.96m
Altre spese	US$14.99m
Guadagni	-US$40.95m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.45
Margine lordo	-1,010.35%
Margine di profitto netto	-1,593.93%
Rapporto debito/patrimonio netto	0%

Come si è comportato I3F nel lungo periodo?

Vedi performance storica e confronto

I3F Panoramica delle azioni

Analisi del rischio

Infinity Pharmaceuticals, Inc. Concorrenti

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

DB:PA8K

€42.8k

XTRA:CNW

€6.5m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.50 loss per share (vs US$0.53 loss in FY 2021)

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2021)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021)

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 1Q 2021)

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings released: US$0.53 loss per share (vs US$0.68 loss in FY 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: €4.00

New 90-day high: €2.00

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

New 90-day high: €1.95

New 90-day high: €1.45

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - €1.03

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Infinity Pharmaceuticals, Inc. Riepilogo dei fondamenti

0.1x

0.0x

Guadagni e ricavi